199 related articles for article (PubMed ID: 36647484)
1. High SERPINH1 expression predicts poor prognosis in lung adenocarcinoma.
Zhang H; Yan X; Gu H; Xue Q; Liu X
J Thorac Dis; 2022 Dec; 14(12):4785-4802. PubMed ID: 36647484
[TBL] [Abstract][Full Text] [Related]
2. Low expression of IL6R predicts poor prognosis for lung adenocarcinoma.
Sun G; Wang T; Shi M; Zhou H; Wang J; Huang Z; Zhang H; Shi J
Ann Transl Med; 2021 Jul; 9(13):1057. PubMed ID: 34422969
[TBL] [Abstract][Full Text] [Related]
3. [Mutational Signatures Analysis of Micropapillary Components and Exploration of ZNF469 Gene in Early-stage Lung Adenocarcinoma with Ground-glass Opacities].
Xu Y; Sun Q; Wang S; Zhu H; Dong G; Meng F; Xia Z; You J; Kong X; Wu J; Chen P; Yuan F; Yu X; Ji J; Li Z; Zhu P; Sun Y; Liu T; Yin R; Xu L
Zhongguo Fei Ai Za Zhi; 2024 Jan; 26(12):889-900. PubMed ID: 38151328
[TBL] [Abstract][Full Text] [Related]
4. Correlation of tumor mutational burden with prognosis and immune infiltration in lung adenocarcinoma.
Li L; Li J
Front Oncol; 2023; 13():1128785. PubMed ID: 36959799
[TBL] [Abstract][Full Text] [Related]
5. A special prognostic indicator: tumor mutation burden combined with immune infiltrates in lung adenocarcinoma with
Fu J; Li Y; Li C; Tong Y; Li M; Cang S
Transl Cancer Res; 2021 Sep; 10(9):3963-3978. PubMed ID: 35116695
[TBL] [Abstract][Full Text] [Related]
6. Integrated analysis and validation reveal ACAP1 as a novel prognostic biomarker associated with tumor immunity in lung adenocarcinoma.
Wang N; Zhu L; Xu X; Yu C; Huang X
Comput Struct Biotechnol J; 2022; 20():4390-4401. PubMed ID: 36051873
[TBL] [Abstract][Full Text] [Related]
7. Construction of a Prognostic Immune-Related LncRNA Risk Model for Lung Adenocarcinoma.
Li Y; Shen R; Wang A; Zhao J; Zhou J; Zhang W; Zhang R; Zhu J; Liu Z; Huang JA
Front Cell Dev Biol; 2021; 9():648806. PubMed ID: 33869203
[TBL] [Abstract][Full Text] [Related]
8. EZH2 as a prognostic-related biomarker in lung adenocarcinoma correlating with cell cycle and immune infiltrates.
Fan K; Zhang BH; Han D; Sun YC
BMC Bioinformatics; 2023 Apr; 24(1):149. PubMed ID: 37069494
[TBL] [Abstract][Full Text] [Related]
9. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
[TBL] [Abstract][Full Text] [Related]
10. Development of a copper metabolism-related gene signature in lung adenocarcinoma.
Chang W; Li H; Zhong L; Zhu T; Chang Z; Ou W; Wang S
Front Immunol; 2022; 13():1040668. PubMed ID: 36524120
[TBL] [Abstract][Full Text] [Related]
11.
Zheng X; Han L; Guan J; Chen C; Zhang Y; Zhang J; Zhang Y; Liu S; Su J; Liu M; Huang H
Front Oncol; 2023; 13():1274439. PubMed ID: 38152367
[TBL] [Abstract][Full Text] [Related]
12. High Expression of
Chen Y; Zhou M; Gu X; Wang L; Wang C
Dis Markers; 2022; 2022():8789515. PubMed ID: 35855850
[TBL] [Abstract][Full Text] [Related]
13. Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma.
Zuo S; Wei M; Wang S; Dong J; Wei J
Front Immunol; 2020; 11():1218. PubMed ID: 32714316
[No Abstract] [Full Text] [Related]
14. Prognostic and immunological role of SERPINH1 in pan-cancer.
Zhong H; Wang Z; Wei X; Liu Y; Huang X; Mo X; Tang W
Front Genet; 2022; 13():900495. PubMed ID: 36105106
[No Abstract] [Full Text] [Related]
15.
Chen P; Quan Z; Song X; Gao Z; Yuan K
Front Oncol; 2022; 12():1005962. PubMed ID: 36300089
[TBL] [Abstract][Full Text] [Related]
16. Pan-cancer analysis of UBE2T with a focus on prognostic and immunological roles in lung adenocarcinoma.
Cao K; Ling X; Jiang X; Ma J; Zhu J
Respir Res; 2022 Nov; 23(1):306. PubMed ID: 36357897
[TBL] [Abstract][Full Text] [Related]
17. Pan-Cancer Integrated Analysis Identification of SASH3, a Potential Biomarker That Inhibits Lung Adenocarcinoma Progression.
Chen X; Yuan Y; Ren W; Zhou F; Huang X; Pu J; Niu X; Jiang X
Front Oncol; 2022; 12():927988. PubMed ID: 35756681
[TBL] [Abstract][Full Text] [Related]
18. HMMR associates with immune infiltrates and acts as a prognostic biomaker in lung adenocarcinoma.
Ma X; Xie M; Xue Z; Yao J; Wang Y; Xue X; Wang J
Comput Biol Med; 2022 Dec; 151(Pt A):106213. PubMed ID: 36306573
[TBL] [Abstract][Full Text] [Related]
19. B3GNT3 as a prognostic biomarker and correlation with immune cell infiltration in lung adenocarcinoma.
Wu Y; Luo J; Li H; Huang Y; Zhu Y; Chen Q
Ann Transl Med; 2022 Mar; 10(6):295. PubMed ID: 35434016
[TBL] [Abstract][Full Text] [Related]
20. Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis.
Li H; Yang L; Wang Y; Wang L; Chen G; Zhang L; Wang D
BMC Bioinformatics; 2023 Apr; 24(1):155. PubMed ID: 37072703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
